Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012. The report serves as a notification of directorate changes and confirms compliance with Listing Rule 9.6.13R regarding the appointment of new Non-Executive Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance update rather than a financial results report.
Material Changes
The primary material change disclosed is the appointment of two new Non-Executive Directors effective July 1, 2012:
- Ms. Lynn Elsenhans
- Ms. Jing Ulrich
The filing also discloses the following holdings in GSK American Depositary Shares (ADS) by the new directors and their connected persons:
- Ms. L. Elsenhans and Mr. J. W. Elsenhans (connected person): 1,000 GSK ADS (jointly held).
- Mr. P. Ulrich (connected person to Ms. J. Ulrich): 338 GSK ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The Company confirms there are no further disclosures to be made under the relevant listing rule regarding these appointments.
Key Facts for Investor Verification
- Two new Non-Executive Directors are scheduled to join the board on July 1, 2012.
- Specific shareholdings in GSK ADS have been disclosed for the new directors and their connected persons.
- This filing contains no financial performance data for the period.